Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Blood and Lymphatic Cancer: Targets and Therapy · 2022-03 · Volume 12 · 7-16
DOI: 10.2147/blctt.s270134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2022-03. Verfasst von Kyaw Hein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Kyaw Hein
Zitieren
APA
Hein, K., Short, N., Jabbour, E., & Yilmaz, M. (2022). Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy, Volume 12, 7-16. https://doi.org/10.2147/blctt.s270134
Vancouver
Hein K, Short N, Jabbour E, Yilmaz M. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy. 2022;Volume 12:7-16. doi:10.2147/blctt.s270134
BibTeX
@article{Hein2022,
author = {Hein, Kyaw and Short, Nicholas and Jabbour, Elias and Yilmaz, Musa},
title = {Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2022},
volume = {Volume 12},
pages = {7--16},
doi = {10.2147/blctt.s270134}
}
EUVIMED